Effects of glucagon-like peptide-1 agonist therapy on vertebral bone mineral density as measured by CT-based Hounsfield units
Despite similar pretreatment BW and HU measurements, all weight loss groups had significant decreases in vertebral HUs following GLP-1 agonist therapy, with a significant correlation observed between HU reduction and treatment duration. This suggests that long-term GLP-1 agonist therapy can significantly diminish spinal BMD regardless of the amount of weight loss achieved.
Authors
- Ahmad Nassr (ORCID: https://orcid.org/0000-0002-7160-734X)
- Arjun S. Sebastian (ORCID: https://orcid.org/0000-0002-6590-7397)
- Michelle J. Clarke (ORCID: https://orcid.org/0000-0003-0358-5633)
- William E. Krauss (ORCID: https://orcid.org/0000-0002-4732-8754)
- Jeremy L. Fogelson (ORCID: https://orcid.org/0000-0002-9118-5607)
- Zach Pennington (ORCID: https://orcid.org/0000-0001-8012-860X)
- A. Hamouda (ORCID: https://orcid.org/0000-0002-1157-6676)
- Michael L. Martini (ORCID: https://orcid.org/0000-0001-8169-7679)
- Kurt A. Kennel (ORCID: https://orcid.org/0000-0002-1507-0832)
- Nikita Lakomkin (ORCID: https://orcid.org/0000-0002-3987-0084)
- Patrick M. Flanigan (ORCID: https://orcid.org/0000-0002-3611-8575)
- Brett A. Freedman (ORCID: https://orcid.org/0000-0002-3408-0163)
- Anthony L. Mikula (ORCID: https://orcid.org/0000-0002-5143-3733)
- Julian S. Rechberger (ORCID: https://orcid.org/0000-0002-0855-3297)
- Melvin D. Helgeson (ORCID: https://orcid.org/0000-0003-0907-1668)
- Benjamin D. Elder
- Jennifer Perez
Institutions
- Mayo Clinic (US)
- Mayo Clinic in Arizona (US)
- Mayo Clinic in Florida (US)
Publication Details
- Journal
- Journal of Neurosurgery Spine
- Published
- 2025-11-21
- DOI
- https://doi.org/10.3171/2025.7.spine25791
- Primary Topic
- Bone health and osteoporosis research
- Type
- article
- Field-Weighted Citation Impact
- 0.00